Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
|Articles|February 11, 2022
Daily Medication Pearl: Edoxaban (Savaysa)
Author(s)Saro Arakelians, PharmD
Edoxaban (Savaysa) can reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Advertisement
Medication Pearl of the Day: Edoxaban (Savaysa)
Indication: Edoxaban (Savaysa) is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).
Insight:
- Dosing:
- For NVAF: The recommended dose is 60 mg once daily in patients with CrCL >50 to ≤ 95 mL/min. Do not use edoxaban in patients with CrCL > 95 mL/min.
- For deep vein thrombosis/pulmonary embolism: The recommended dose is 60 mg once daily (2.2). The recommended dose is 30 mg once daily for patients with CrCL 15 to 50 mL/min or body weight less than or equal to 60 kg or who use certain P-gp inhibitors.
- Dosage forms: Tablets 60 mg, 30 mg, and 15 mg.
- Adverse events: Bleeding, rash, abnormal liver function.
- Mechanism of action: Edoxaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity.
- Manufacturer: Daiichi Sankyo
Sources:
Advertisement
Related to this article
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during cold and influenza season.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
2
Beyond Prescription Volume: Measuring the Pharmacist’s Value
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5